[DOI: 10.1126/science.283.5409.1849b]

Science Over Politics

Last month, 70 members of the U.S. Congress, including Henry Hyde, Chairman of the House Judiciary Committee, and J. C. Watts Jr., Republican Conference Chairman, signed a letter urging the federal government to ban all research on stem cells obtained from human embryos and fetuses. The letter calls upon the U.S. Department of Health and Human Services (DHHS) to reverse National Institutes of Health (NIH) Director Harold Varmus's decision to allow funding of pluripotent stem cell research. The lawmakers object "in the strongest possible terms" to Varmus's decision, as well as to the memorandum issued in January by DHHS General Counsel Harriet Rabb, which served as the legal basis for Varmus's position. In their letter, the members of Congress state, "Any NIH action to initiate funding of such research would violate both the letter and spirit of the federal law banning federal support for research in which human embryos are harmed or destroyed." Federal laws and regulations, they claim, have protected human embryos and fetuses "from harmful experimentation at the hands of the Federal government" for more than two decades. "This area of law has provided a bulwark against government's misuse and exploitation of human beings in the name of medical progress. It would he a travesty for this Administration to attempt to unravel this accepted ethical standard."
Human embryonic stem cells differentiated to various cell types, including (clockwise, from upper left) gut, neural, striated muscle, and kidney cells.

CREDIT: J. A. THOMSON

We the undersigned urge the Administration and DHHS to support Varmus's decision to allow federal funds to be used for research using human pluripotent stem cells. NIH fully understands and respects the important ethical and moral issues raised by stem cell research and, indeed, has announced plans "to move forward in a careful and deliberate fashion to develop rigorous guidelines that address the special ethical, legal, and moral issues surrounding this research." Before funding any research using pluripotent stem cells, NIH plans to convene a special oversight group to review all research grant applications in this area. In addition to two thoughtful sets of guidelines that already exist--the 1994 Report of the Human Embryo Research Panel and the regulations regarding Research on Transplantation of Fetal Tissue (section 498A of the Public Health Services Act)--NIH will consider advice from the National Bioethics Advisory Commission (NBAC), the newly established Council of Public Representatives (COPR), the public, and Congress.

We join with other scientific organizations and patient groups in our belief that DHHS's current position is both laudable and forward-thinking. It succeeds in protecting the sanctity of human life without impeding biomedical research that could be profoundly important to the understanding and treatment of human disease. In addition to helping to unravel processes underlying cell differentiation and biological development (which, in turn, could lead to new ways to prevent and treat birth defects and cancer), the use of human pluripotent stem cells could potentially reduce the number of animal studies and clinical trials required for drug development and testing. The implications of this research for clinical medicine are equally enormous. Stem cells could be used to generate a long list of cells and tissues that could be used for transplantation. Myocardiocytes, for instance, could be injected into the heart, to heal myopathies and scars; neurons could be transplanted into the brains of patients with neurodegenerative disorders such as Parkinson's disease; and insulin-producing beta cells could be used to treat--or perhaps even cure--patients with diabetes. DHHS must remain diligent in allowing pluripotent stem cell research to go forward. If Congress succeeds in reversing Varmus's decision, these
tremendous scientific and medical benefits may never become available to the patients who so desperately need them.

Robert P. Lanza* (corresponding author),
Clinton, MA 01510, USA.
E-mail: BobLanza@aol.com;
Kenneth J. Arrow,†
Stanford University,
Stanford, CA 94309, USA;
Julius Axelrod,†
National Institute of Mental Health,
Bethesda, MD 20892, USA;
David Baltimore,†
California Institute of Technology,
Pasadena, CA 91125, USA;
Baruj Benacerraf,†
Dana-Farber Cancer Institute,
Boston, MA 02215, USA;
Konrad E. Bloch,†
Harvard University,
Cambridge, MA 02138, USA;
Nicolaas Bloembergen,†
Harvard University;
Herbert C. Brown,†
Purdue University,
West Lafayette, IN 47907, USA;
Michael S. Brown,†
University of Texas Southwestern Medical Center,
Dallas, TX 75235, USA;
Jose B. Cibelli,
Advanced Cell Technology,
Worcester, MA 01605, USA;
Stanley Cohen,†
Vanderbilt University School of Medicine,
Nashville, TN 37232, USA;
Leon N. Cooper,†
Brown University,
Providence, RI 02912, USA;
E. J. Corey,†
Harvard University;
Reneto Dulbecco,†
Salk Institute,
La Jolla, CA 92037, USA;
Edmond H. Fischer,†
University of Washington,
Seattle, WA 98195, USA;
Val L. Fitch,†
Princeton University,
Princeton, NJ 08544, USA;
Jerome I. Friedman,†
Massachusetts Institute of Technology,
Cambridge, MA 02139, USA;
Milton Friedman,†
Hoover Institute,
Stanford, CA 94305, USA;
Robert F. Furchgott,†
State University of New York,
Brooklyn, NY 11203, USA;
Murray Gell-Mann,†
Santa Fe, NM 87501, USA;
Donald A. Glaser,†
University of California,
Berkeley, CA 94720, USA;
Sheldon Lee Glashow,†
Harvard University;
Walter Gilbert,†
Harvard University;
Joseph L. Goldstein,†
University of Texas Southwestern Medical Center;
Stephen Jay Gould,
Harvard University;
Roger Guillemin,†
Salk Institute;
Herbert A. Hauptman,†
Hauptman-Woodward Medical Research,
Buffalo, NY 14203, USA;
Dudley Herschbach,†
Harvard University;
Roald Hoffman,†
Cornell University,
Ithaca, NY 14853, USA;
Leroy Hood,
University of Washington,
Seattle;
David H. Hubel,†
Harvard Medical School,
Boston, MA 02115, USA;
Jerome Karle,†
Washington, DC 20375, USA;
Lawrence R. Klein,†
University of Pennsylvania,
Philadelphia, PA 19104, USA;
Walter Kohn,†
University of California,
Santa Barbara, CA 93106, USA;
Arthur Kornberg,†
Stanford University School of Medicine,
Stanford, CA 94305, USA;
Edwin G. Krebs,†
University of Washington,
Seattle;
Leon M. Lederman,†
Illinois Institute of Technology,
Chicago, IL 60616, USA;
Joshua Lederberg,†
Rockefeller University,
New York, NY 10021, USA;
David M. Lee,†
Cornell University;
Robert E. Lucas Jr.,†
University of Chicago,
Chicago, IL 60637, USA;
Rudolph A. Marcus,†
California Institute of Technology;
R. Bruce Merrifield,†
Rockefeller University;
Merton H. Miller,†
University of Chicago;
Franco Modigliani,†
Mario J. Molina,†
Massachusetts Institute of Technology;
Kary Mullis,†
La Jolla, CA 92037, USA;
Ferid Murad,†
University of Texas Medical School,
Houston, TX 75225, USA;
Joseph E. Murray,†
Harvard Medical School;
Daniel Nathans,†
Johns Hopkins University,
Baltimore, MD 21205, USA;
Marshall W. Nirenberg,†
National Heart, Lung, and Blood Institute,
Bethesda, MD 20892, USA;
Douglas C. North,†
Washington University,
St. Louis, MO 63130, USA;
George A. Olah,†
University of Southern California,
Los Angeles, CA 90007, USA;
George E. Palade,†
University of California,
San Diego, CA 92093, USA;
Martin J. Perl,†
Stanford University;
Norman F. Ramsey,†
Harvard University;
Burton Richter,†
Stanford University;
Richard J. Roberts,†
New England Biolabs,
Beverly, MA 01915, USA;
James M. Robl,
University of Massachusetts,
Amherst, MA 01003, USA;
Paul A. Samuelson,†
Massachusetts Institute of Technology;
Melvin Schwartz,†
Brown University;
Phillip A. Sharp,†
Massachusetts Institute of Technology;
Richard E. Smalley,†
Rice University,
Houston, TX 77005, USA;
Hamilton O. Smith,†
Johns Hopkins School of Medicine,
Baltimore, MD 21205, USA;
Robert M. Solow,†
Massachusetts Institute of Technology;
Henry Taube,†
Stanford University;
Susumu Tonegawa,†
Massachusetts Institute of Technology;
James D. Watson,†
Cold Spring Harbor Laboratory,
Editors' note

Stem cell research is one of the areas being pursued by the company Advanced Cell Technology. Another letter supporting stem cell research, led by Paul Berg, representing the American Society for Cell Biology, and signed by 36 Nobel laureates (many of them also signers of the above letter) was sent directly to President Clinton and Congress on 8 March.